Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May;12(5):1770-1775.
doi: 10.21037/jtd-20-1661.

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?

Kenichi Suda  1 , Tetsuya Mitsudomi  1
Affiliations
Editorial

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?

Kenichi Suda et al. J Thorac Dis. 2020 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1661). KS reports grants and personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, grants from Rain Therapeutics, outside the submitted work; TM reports grants and personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, grants and personal fees from Pfizer Japan Inc., grants and personal fees from Chugai Pharmaceutical Co. Ltd., personal fees from MSD K. K., grants and personal fees from Ono Pharmaceutical Co. Ltd., personal fees from Bristol Myers Squibb, personal fees from Eli Lilly Japan K. K., grants and personal fees from Taiho Pharmaceutical Co. Ltd., outside the submitted work.

Comment on

References

    1. Suda K, Kim J, Murakami I, et al. Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naive Lesions. J Thorac Oncol 2018;13:1496-507. 10.1016/j.jtho.2018.05.039 - DOI - PMC - PubMed
    1. Biswas D, Birkbak NJ, Rosenthal R, et al. A clonal expression biomarker associates with lung cancer mortality. Nat Med 2019;25:1540-8. 10.1038/s41591-019-0595-z - DOI - PMC - PubMed
    1. Aggarwal C, Rodriguez Abreu D, Felip E, et al. 1060P – Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. Presented at ESMO 2016, 2016.
    1. Saito Y, Horiuchi S, Morooka H, et al. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. J Thorac Dis 2019;11:4982-91. 10.21037/jtd.2019.12.24 - DOI - PMC - PubMed
    1. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol 2018;13:1302-11. 10.1016/j.jtho.2018.05.013 - DOI - PMC - PubMed